Posted inCardiology news
Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrential TR.












![Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy](https://news.medxy.ai/wp-content/uploads/2026/04/d43c8ff0-6629-4944-bc15-78efd79810d7.jpg)






